DE4394931T1 - Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen - Google Patents

Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen

Info

Publication number
DE4394931T1
DE4394931T1 DE4394931T DE4394931T DE4394931T1 DE 4394931 T1 DE4394931 T1 DE 4394931T1 DE 4394931 T DE4394931 T DE 4394931T DE 4394931 T DE4394931 T DE 4394931T DE 4394931 T1 DE4394931 T1 DE 4394931T1
Authority
DE
Germany
Prior art keywords
treatment
norastemizole
allergic diseases
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE4394931T
Other languages
English (en)
Inventor
Raymond L Woosley
A K Gunnar Aberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Georgetown University
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University, Sepracor Inc filed Critical Georgetown University
Publication of DE4394931T1 publication Critical patent/DE4394931T1/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
DE4394931T 1992-09-03 1993-09-03 Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen Ceased DE4394931T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94005492A 1992-09-03 1992-09-03
PCT/US1993/008349 WO1994007495A1 (en) 1992-09-03 1993-09-03 Use of norastemizole for the treatment of allergic disorders

Publications (1)

Publication Number Publication Date
DE4394931T1 true DE4394931T1 (de) 1995-07-20

Family

ID=25474141

Family Applications (3)

Application Number Title Priority Date Filing Date
DE4394931T Ceased DE4394931T1 (de) 1992-09-03 1993-09-03 Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
DE69333387T Expired - Fee Related DE69333387T2 (de) 1992-09-03 1993-09-03 Pharmazeutische Zusammensetzungen enthaltend Norastemizol.
DE69327328T Expired - Fee Related DE69327328T2 (de) 1992-09-03 1993-09-03 Verwendund von norastemizol zur behandlung der allergischen rhinitis

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69333387T Expired - Fee Related DE69333387T2 (de) 1992-09-03 1993-09-03 Pharmazeutische Zusammensetzungen enthaltend Norastemizol.
DE69327328T Expired - Fee Related DE69327328T2 (de) 1992-09-03 1993-09-03 Verwendund von norastemizol zur behandlung der allergischen rhinitis

Country Status (13)

Country Link
US (5) US6130233A (de)
EP (3) EP0658110B1 (de)
JP (3) JPH08501083A (de)
AT (2) ATE187642T1 (de)
AU (1) AU687746B2 (de)
CA (1) CA2143610C (de)
DE (3) DE4394931T1 (de)
DK (2) DK0920865T3 (de)
ES (2) ES2139673T3 (de)
GB (1) GB2285219B (de)
GR (1) GR3032541T3 (de)
PT (2) PT658110E (de)
WO (1) WO1994007495A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en) 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
NZ527200A (en) * 1997-03-26 2004-12-24 Sepracor Inc Stable norastemizole formulations including a super disintegrant
US6248308B1 (en) * 1998-04-14 2001-06-19 Sepracor Inc. Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
JP2004534820A (ja) * 2001-06-20 2004-11-18 シェーリング　コーポレイション 鼻うっ血および鼻閉塞の処置のための抗ヒスタミン薬
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
US20080207593A1 (en) * 2007-02-28 2008-08-28 Collegium Pharmaceutical, Inc. Antihistamine Combination
US20080306116A1 (en) * 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
HUE029444T2 (en) 2008-01-04 2017-02-28 Schabar Res Ass Llc A composition containing an analgesic and an antihistamine
US8241616B2 (en) * 2008-04-03 2012-08-14 Rohm And Haas Company Hair styling composition
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
EP4181912A1 (de) 2020-07-15 2023-05-24 Schabar Research Associates LLC Orale einzeldosiszusammensetzungen aus ibuprofen und famotidin zur behandlung von akutem schmerz und zur verminderung der schwere und/oder des risikos von sodbrennen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219559A (en) * 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
DE3484096D1 (de) * 1983-11-30 1991-03-14 Janssen Pharmaceutica Nv Bizyklisches heterozyklyl aufveisende n-(bizyklisches heterozyklyl-4-piperidinamine.
US4835161A (en) * 1986-02-03 1989-05-30 Janssen Pharmaceutica N.V. Anti-histaminic compositions containing n-heterocyclyl-4-piperidinamines
EP0232937B1 (de) * 1986-02-03 1992-08-19 Janssen Pharmaceutica N.V. N-Heterozyklische-4-piperidinamine enthaltende anti-histaminische Zusammensetzungen
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
EP1041990B1 (de) 1997-12-23 2006-06-28 Schering Corporation Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum

Also Published As

Publication number Publication date
US6130233A (en) 2000-10-10
EP0920865B1 (de) 2004-01-14
GB2285219A (en) 1995-07-05
ES2210957T3 (es) 2004-07-01
DE69327328T2 (de) 2000-06-21
GB2285219B (en) 1996-09-11
JP2002255817A (ja) 2002-09-11
EP1262183A1 (de) 2002-12-04
ES2139673T3 (es) 2000-02-16
DE69333387D1 (de) 2004-02-19
GB9504329D0 (en) 1995-04-26
JP2002308772A (ja) 2002-10-23
AU4848093A (en) 1994-04-26
US6187795B1 (en) 2001-02-13
PT658110E (pt) 2000-06-30
DK0658110T3 (da) 2000-04-17
ATE257704T1 (de) 2004-01-15
JPH08501083A (ja) 1996-02-06
WO1994007495A1 (en) 1994-04-14
US6187794B1 (en) 2001-02-13
DK0920865T3 (da) 2004-04-19
EP0658110A1 (de) 1995-06-21
US6124320A (en) 2000-09-26
ATE187642T1 (de) 2000-01-15
PT920865E (pt) 2004-06-30
DE69327328D1 (de) 2000-01-20
CA2143610A1 (en) 1994-04-14
DE69333387T2 (de) 2004-12-09
AU687746B2 (en) 1998-03-05
US6268382B1 (en) 2001-07-31
CA2143610C (en) 2004-08-24
GR3032541T3 (en) 2000-05-31
EP0920865A1 (de) 1999-06-09
EP0658110B1 (de) 1999-12-15

Similar Documents

Publication Publication Date Title
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
ATE162399T1 (de) Terfanadin metaboliten und deren optisch reine isomere zur behandlung von allergischen krankheiten
DE68912459T2 (de) Verwendung von Thromboxan-A2-Rezeptorantagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hautkrankheiten.
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
KR890001555A (ko) 요산 배설용 조성물

Legal Events

Date Code Title Description
8127 New person/name/address of the applicant

Owner name: SEPRACOR INC., MARLBOROUGH, MASS., US

8110 Request for examination paragraph 44
8607 Notification of search results after publication
8131 Rejection